GlucoTrack Inc. (Nasdaq: GCTK) reported its financial results for the first quarter ending March 31, 2025. The company recorded a net loss of $6.8 million, compared to a net loss of $2.9 million in the same period of the previous year. This increase in net loss is primarily due to a non-cash $3.4 million change in the fair value of derivative liabilities and a $0.5 million increase in operating expenses. Research and development expenses decreased to $1.9 million from $2.1 million in the first quarter of 2024, mainly due to timing in product and manufacturing development activities. Meanwhile, marketing, general and administrative expenses rose to $1.6 million, up from $0.8 million in the same quarter last year, driven by increased legal and professional fees and personnel costs. GlucoTrack highlighted progress in its business operations, notably receiving ethical approval in Australia to start a long-term clinical study of its continuous blood glucose monitor (CBGM) in participants with type 1 and type 2 diabetes. The company plans to implant the first patients in its long-term, multicenter feasibility study of the fully implantable CBGM system in Australia by the third quarter of 2025. Additionally, GlucoTrack anticipates obtaining Investigational Device Exemption $(IDE)$ approval for its novel CBGM technology from the FDA in the fourth quarter of 2025. As of March 31, 2025, GlucoTrack's cash and cash equivalents were $9.1 million, an increase from $5.6 million at the end of 2024. This rise in cash reserves was due to $6.4 million received from financing activities, offset by $2.9 million used in operating and investing activities. The company believes its current cash position will be sufficient to support its 2025 operating plans, including initiating human clinical trials and achieving related milestones.